

# Maurie Markman

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/325832/maurie-markman-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

311  
papers

6,360  
citations

34  
h-index

78  
g-index

390  
ext. papers

7,000  
ext. citations

4  
avg, IF

6.05  
L-index

#	Paper	IF	Citations
311	Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1001-7	2.2	860
310	Ovarian cancer. <i>Lancet, The</i> , <b>2009</b> , 374, 1371-82	4.0	477
309	Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2110-5	2.2	386
308	Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research community. <i>Oncologist</i> , <b>2004</b> , 9, 3-7	5.7	309
307	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3570-6	2.2	290
306	Clinical features of hypersensitivity reactions to carboplatin. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 1141-2	2.2	277
305	Second-line treatment of ovarian cancer. <i>Oncologist</i> , <b>2000</b> , 5, 26-35	5.7	243
304	Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1460-6	2.2	196
303	Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3120-5	2.2	185
302	Intraperitoneal antineoplastic drug delivery: rationale and results. <i>Lancet Oncology, The</i> , <b>2003</b> , 4, 277-83	21.7	183
301	Phase II trial of weekly paclitaxel (80 mg/m <sup>2</sup> ) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2006</b> , 101, 436-40	4.9	176
300	Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 988-94	2.2	151
299	The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , <b>1999</b> , 74, 272-7	4.9	146
298	Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 102-5	2.2	139
297	Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>1992</b> , 45, 284-9	4.9	136
296	Prevention and management of antineoplastic-induced hypersensitivity reactions. <i>Drug Safety</i> , <b>2001</b> , 24, 767-79	5.1	129
295	Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4611-4	2.2	121

294	Toxicities of the platinum antineoplastic agents. <i>Expert Opinion on Drug Safety</i> , <b>2003</b> , 2, 597-607	4.1	110
293	Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m <sup>2</sup> ) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. <i>Gynecologic Oncology</i> , <b>2009</b> , 114, 195-8	4.9	104
292	Managing taxane toxicities. <i>Supportive Care in Cancer</i> , <b>2003</b> , 11, 144-7	3.9	103
291	Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. <i>Gynecologic Oncology</i> , <b>2003</b> , 90, 593-6	4.9	97
290	Pharmaceutical management of ovarian cancer : current status. <i>Drugs</i> , <b>2008</b> , 68, 771-89	12.1	83
289	Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1901-5	2.2	78
288	Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. <i>Cancer</i> , <b>1993</b> , 71, 634-7	6.4	58
287	Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. <i>Gynecologic Oncology</i> , <b>2006</b> , 100, 133-8	4.9	51
286	An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1999</b> , 125, 427-9	4.9	51
285	Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. <i>Gynecologic Oncology</i> , <b>2004</b> , 93, 699-701	4.9	49
284	Management of toxicities associated with the administration of taxanes. <i>Expert Opinion on Drug Safety</i> , <b>2003</b> , 2, 141-6	4.1	49
283	Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. <i>Trends in Pharmacological Sciences</i> , <b>2008</b> , 29, 515-9	13.2	45
282	Intraperitoneal drug delivery of antineoplastics. <i>Drugs</i> , <b>2001</b> , 61, 1057-65	12.1	45
281	Safety issues in using complementary and alternative medicine. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 39S-41S	2.2	45
280	An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3615-20	2.2	39
279	Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2004</b> , 130, 25-8	4.9	39
278	Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4168-70	2.2	34
277	Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2000</b> , 77, 112-5	4.9	34

276	Tumor chemosensitivity and chemoresistance assays. <i>Cancer</i> , <b>1996</b> , 77, 1020-5	6.4	33
275	The Role of CA-125 in the Management of Ovarian Cancer. <i>Oncologist</i> , <b>1997</b> , 2, 6-9	5.7	32
274	Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 93, 390-3	4.9	31
273	Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , <b>2003</b> , 91, 573-6	4.9	31
272	Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m <sup>2</sup> over 3 h) employed in the treatment of gynecologic malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2001</b> , 127, 55-8	4.9	30
271	Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2013</b> , 131, 241-5	4.9	26
270	Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1999</b> , 125, 697-8	4.9	26
269	Optimizing primary chemotherapy in ovarian cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2003</b> , 17, 957-68, viii	3.1	24
268	Chemoradiation in the management of cervix cancer: current status and future directions. <i>Oncology</i> , <b>2013</b> , 84, 246-50	3.6	23
267	New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. <i>Oncologist</i> , <b>2007</b> , 12, 186-90	5.7	21
266	Pharmaceutical Management of Ovarian Cancer: Current Status. <i>Drugs</i> , <b>2019</b> , 79, 1231-1239	12.1	19
265	Optimal management of recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19 Suppl 2, S40-3	3.5	19
264	Maintenance chemotherapy in the management of epithelial ovarian cancer. <i>Cancer and Metastasis Reviews</i> , <b>2015</b> , 34, 11-7	9.6	18
263	When regulatory requirements conflict with ethical study design: the case of oral ondansetron. <i>Cancer Investigation</i> , <b>1994</b> , 12, 654-6	2.1	18
262	Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. <i>Gynecologic Oncology</i> , <b>2004</b> , 94, 404-8	4.9	17
261	Chronic administration of single-agent paclitaxel in gynecologic malignancies. <i>Gynecologic Oncology</i> , <b>2001</b> , 81, 201-5	4.9	17
260	Advances in cervical cancer pharmacotherapies. <i>Expert Review of Clinical Pharmacology</i> , <b>2014</b> , 7, 219-23	3.8	15
259	Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. <i>Oncology</i> , <b>2004</b> , 66, 343-6	3.6	13

258	Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , <b>2015</b> , 8, 466-71	1	12
257	An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2009</b> , 15, 105-9	2.2	11
256	A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2005</b> , 131, 26-30	4.9	11
255	Intraperitoneal Therapy of Ovarian Cancer. <i>Oncologist</i> , <b>1996</b> , 1, 18-21	5.7	11
254	Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging?. <i>Current Oncology Reports</i> , <b>2014</b> , 16, 396	6.3	10
253	Antiangiogenic drugs in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 2269-77	4	10
252	Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. <i>Gynecologic Oncology</i> , <b>2004</b> , 92, 180-2	4.9	10
251	Role of intraperitoneal chemotherapy in the front-line setting. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 145s-148s	2.2	10
250	Intraperitoneal chemotherapy in the treatment of ovarian cancer. <i>Annals of Medicine</i> , <b>1996</b> , 28, 293-6	1.5	10
249	HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. <i>Journal of Gastrointestinal Oncology</i> , <b>2014</b> , 5, E103-8	2.8	10
248	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden. <i>Lung Cancer: Targets and Therapy</i> , <b>2018</b> , 9, 45-47	2.9	9
247	Limitations to the use of the CA-125 antigen level in ovarian cancer. <i>Current Oncology Reports</i> , <b>2003</b> , 5, 263-4	6.3	9
246	Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. <i>Cancer Management and Research</i> , <b>2011</b> , 3, 219-25	3.6	9
245	Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions. <i>Reviews on Recent Clinical Trials</i> , <b>2007</b> , 2, 169-73	1.2	9
244	Self-forgiveness is associated with reduced psychological distress in cancer patients and unmatched caregivers: Hope and self-blame as mediating mechanisms. <i>Journal of Psychosocial Oncology</i> , <b>2017</b> , 35, 544-560	2.8	8
243	Counterpoint: chemosensitivity assays for recurrent ovarian cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2011</b> , 9, 121-4	7.3	8
242	Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: time for an evidence-based comparison. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 6-7	4.9	8
241	Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1997</b> , 123, 224-6	4.9	8

240	Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 420-425	4.9	7
239	Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: report of two cases. <i>Case Reports in Oncology</i> , <b>2014</b> , 7, 550-4	1	7
238	Information overload in oncology practice and its potential negative impact on the delivery of optimal patient care. <i>Current Oncology Reports</i> , <b>2011</b> , 13, 249-51	6.3	7
237	Serious ethical dilemma of single-agent pegylated liposomal Doxorubicin employed as a control arm in ovarian cancer chemotherapy trials. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e319-20; author reply e321-2	2.2	7
236	The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature. <i>Cancer</i> , <b>2007</b> , 109, 1929-32	6.4	7
235	Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. <i>Gynecologic Oncology</i> , <b>2004</b> , 95, 109-13	4.9	7
234	Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia. <i>Gynecologic Oncology</i> , <b>2003</b> , 91, 118-22	4.9	7
233	Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies. <i>Cancer</i> , <b>2003</b> , 98, 885-7	6.4	7
232	Cardio-Oncology: mechanisms of cardiovascular toxicity. <i>F1000Research</i> , <b>2018</b> , 7, 113	3.6	7
231	Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. <i>Women's Health</i> , <b>2018</b> , 14, 1745505717750694	3	6
230	Commentary: Implications of cancer managed as a "chronic illness". <i>Current Oncology Reports</i> , <b>2011</b> , 13, 90-1	6.3	6
229	Taxanes in the management of gynecologic malignancies. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 219-26	3.5	5
228	Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 93, 715-7	4.9	5
227	Second-line therapy of ovarian cancer with Paclitaxel administered by both the intravenous and intraperitoneal routes: rationale and case reports. <i>Gynecologic Oncology</i> , <b>2002</b> , 86, 95-8	4.9	5
226	Consolidation/maintenance chemotherapy for ovarian cancer. <i>Current Oncology Reports</i> , <b>2003</b> , 5, 454-8	6.3	5
225	Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies?. <i>Cancer Investigation</i> , <b>1995</b> , 13, 625-8	2.1	5
224	Second-line chemotherapy for refractory cancer: intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , <b>1994</b> , 10, 299-304		5
223	The needs of science vs the needs of patients: ethical concerns in cancer clinical trials. <i>Cleveland Clinic Journal of Medicine</i> , <b>2003</b> , 70, 1008-9, 1013-4, 1016	2.8	5

222	Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation. <i>Case Reports in Oncology</i> , <b>2017</b> , 10, 840-845	1	4
221	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2012</b> , 124, 171; author reply 171-2	4.9	4
220	The Role of Angiogenesis in Cancer <b>2015</b> , 64-71		4
219	Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?. <i>Cancer Investigation</i> , <b>2004</b> , 22, 471-3	2.1	4
218	Rationale for maintenance or consolidation therapy in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2003</b> , 1, 176-8	0.6	4
217	Pegylated liposomal Doxorubicin-induced acute transient encephalopathy in a patient with breast cancer: a case report. <i>Case Reports in Oncology</i> , <b>2014</b> , 7, 228-32	1	3
216	Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown. <i>Gynecologic Oncology</i> , <b>2011</b> , 122, 213-4	4.9	3
215	Presentation of chemotherapy options for cervix cancer on cancer-related Internet sites. <i>Journal of Women's Health</i> , <b>2009</b> , 18, 827-9	3	3
214	The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 628-9		3
213	Prolonged Disease-Free and Treatment-Free Survival in Platinum-Resistant Ovarian Cancer Following Extended (> 1 Year) Administration of Single-Agent Paclitaxel: A Case Report and Discussion of Potential Clinical Implications. <i>Cancer Investigation</i> , <b>2005</b> , 23, 33-35	2.1	3
212	Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process: ethical conflict in drug approval. <i>Cancer</i> , <b>2003</b> , 98, 215-8	6.4	3
211	Limits to the "benefits" from our oncologic interventions: a case report. <i>Gynecologic Oncology</i> , <b>2000</b> , 78, 261-2	4.9	3
210	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?. <i>Oncologist</i> , <b>2016</b> , 21, 529-31	5.7	3
209	The Evolving Arena of Ovarian Cancer Maintenance Therapy. <i>Oncology</i> , <b>2019</b> , 97, 202-205	3.6	2
208	The Role of microRNAs in Cancer <b>2015</b> , 80-88		2
207	Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 9, 69-70	19.4	2
206	An Example of Ovarian Cancer as a Chronic Disease Process: 11-Year Survival with Multiple Treatments for Recurrent and Progressive Disease. <i>Case Reports in Oncology</i> , <b>2008</b> , 1, 1-4	1	2
205	Second-line chemotherapy of epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2003</b> , 3, 31-6	3.5	2

204	The Requirement for Increasingly Effective Societal Cancer Control Efforts. <i>Current Oncology Reports</i> , <b>2018</b> , 20, 9	6.3	1
203	Ovarian cancer survival: steady improvement, despite rhetoric to the contrary. <i>Current Oncology Reports</i> , <b>2013</b> , 15, 433-5	6.3	1
202	Optimism and the continued promise of maintenance chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 879-880	3.5	1
201	Chronic Lymphocytic Leukemia <b>2015</b> , 130-144		1
200	Renal Cell Carcinoma and Targeted Therapy <b>2015</b> , 287-295		1
199	Cancer Stem Cell Principles <b>2015</b> , 39-46		1
198	Acute Myeloid Leukemia <b>2015</b> , 89-100		1
197	Metastatic Breast Cancer with Extensive Osseous Metastasis Presenting with Symptomatic Immune Thrombocytopenic Purpura and Anemia: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , <b>2015</b> , 8, 256-63	1	1
196	Induction Therapy in Acute Myeloid Leukemia <b>2014</b> , 58-66		1
195	Challenging the requirements for disclosing risk to clinical research participants. <i>American Journal of Bioethics</i> , <b>2014</b> , 14, 11-2	1.1	1
194	Radiotherapy for Head and Neck Cancers <b>2014</b> , 759-766		1
193	Carcinoma of Unknown Primary (CUP) <b>2014</b> , 815-821		1
192	Management of cancer in the elderly: an essential need for more clinically relevant data. <i>Oncology</i> , <b>2013</b> , 85, 166-7	3.6	1
191	Involvement of bone in epithelial ovarian cancer: case report of an uncommon late metastatic event. <i>Case Reports in Oncology</i> , <b>2011</b> , 4, 490-1	1	1
190	Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology. <i>Cancer</i> , <b>2007</b> , 109, 1003-6	6.4	1
189	New developments in the anti-neoplastic drug management of ovarian cancer. <i>F1000prime Reports</i> , <b>2013</b> , 5, 48		1
188	HPV vaccination as a strategy for cancer prevention. <i>Future Virology</i> , <b>2020</b> , 15, 67-70	2.4	1
187	Are we winning or losing the war on cancer?. <i>Cleveland Clinic Journal of Medicine</i> , <b>2003</b> , 70, 632-3	2.8	1



186	Assessing cancer clinical trials: will your patient benefit from a breakthrough? <i>Cleveland Clinic Journal of Medicine</i> , <b>2002</b> , 69, 368-9, 375-6	2.8	1
185	Update on the utility of prognostic biomarkers in ovarian cancer. <i>F1000 Medicine Reports</i> , <b>2009</b> , 1,		1
184	Lapatinib as a therapeutic option in brain metastases from HER2+ breast cancer. <i>Annals of Palliative Medicine</i> , <b>2013</b> , 2, 35-6	1.7	1
183	A Case Report Demonstrating the Potential Clinical Relevance of Liquid Tumor Biopsies in Lung Cancer. <i>Case Reports in Oncology</i> , <b>2016</b> , 9, 714-717	1	0
182	Case of Ovarian Cancer in a Woman with Undiagnosed Graves Disease: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , <b>2017</b> , 10, 452-454	1	
181	Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies. <i>Women's Health</i> , <b>2016</b> , 12, 396-9	3	
180	Acquired Aplastic Anemia <b>2014</b> , 131-134		
179	Primary CNS Lymphoma <b>2014</b> , 308-315		
178	Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia <b>2014</b> , 180-186		
177	Management of Acute Promyelocytic Leukemia <b>2014</b> , 71-75		
176	Diffuse Large B-Cell Lymphoma <b>2014</b> , 263-269		
175	Dangers of "confirmatory" cancer trials that fail to actually test the original hypothesis. <i>Current Oncology Reports</i> , <b>2014</b> , 16, 381	6.3	
174	An experience with managing cancer patients reportedly previously informed of the absence of additional available antineoplastic therapeutic options. <i>Case Reports in Oncology</i> , <b>2014</b> , 7, 633-7	1	
173	Provider impact on survival outcomes in the management of malignant disease. <i>Current Oncology Reports</i> , <b>2013</b> , 15, 193-6	6.3	
172	Targeted Therapy in Solid Tumors: Lung Cancer <b>2015</b> , 224-230		
171	Toward Personalized Therapy for Cancer <b>2015</b> , 3-13		
170	Targeted and Functional Imaging <b>2015</b> , 101-110		
169	Targeted Therapies in Chronic Myeloid Leukemia <b>2015</b> , 111-120		

- 168 Targeted Therapy for Acute Lymphoblastic Leukemia **2015**, 121-129
- 167 The Impact of Genomics on Targeted Therapy in Multiple Myeloma and Lymphomas **2015**, 157-161
- 166 Targeted Therapy in Myelodysplastic Syndromes **2015**, 162-168
- 165 Lymphoma and Targeted Therapies **2015**, 169-176
- 164 Targeted Therapy in Solid Tumors: Brain **2015**, 177-189
- 163 Targeted Therapy for Breast Cancer **2015**, 190-192
- 162 Combining Targeted Therapies **2015**, 14-26
- 161 Targeted Therapy in Solid Tumors: Colorectal Cancer **2015**, 193-204
- 160 Targeted Therapy in Solid Tumors: Head and Neck **2015**, 216-223
- 159 Targeted Therapy in Melanoma **2015**, 231-239
- 158 Molecular Therapeutics: Pancreatic Cancer **2015**, 255-262
- 157 Targeted Therapies for Pediatric Solid Tumors **2015**, 263-272
- 156 Principles of Targeted Immunotherapy **2015**, 27-38
- 155 Targeted Therapy in Solid Tumors: Sarcomas **2015**, 296-301
- 154 RAS-RAF-MEK Pathway: Aberrations and Therapeutic Possibilities **2015**, 303-314
- 153 The Phosphatidylinositol 3-Kinase Pathway in Human Malignancies **2015**, 315-324
- 152 Current Status and Future Direction of PARP Inhibition in Cancer Therapy **2015**, 325-340
- 151 Targeting the c-Met Kinase **2015**, 341-346

150 KIT Kinase **2015**, 347-352

149 TP53 **2015**, 353-359

148 The Tumor Microenvironment as a Target for Therapeutic Intervention **2015**, 47-63

147 Epigenetics and Epigenetic Therapy of Cancer **2015**, 72-79

146 Naturopathic Medicine in Oncology **2014**, 879-883

145 Cancer Survivorship and Psychosocial Issues in Oncology **2014**, 896-901

144 Musculoskeletal Care in Oncology **2014**, 893-895

143 Anesthesiology Consultation for Localized Cancer Pain **2014**, 884-892

142 Pitfalls in the Diagnosis of Myelodysplastic Syndromes **2014**, 97-105

141 Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia **2014**, 40-47

140 Minimal Residual Disease in Acute Lymphoblastic Leukemia **2014**, 35-39

139 Management of T-Cell Acute Lymphoblastic Leukemia **2014**, 29-34

138 Management of B-Cell Acute Lymphoblastic Leukemia **2014**, 22-28

137 Prognostic Markers and Models in Acute Lymphoblastic Leukemia **2014**, 18-21

136 Consolidation Therapy in Acute Myeloid Leukemia **2014**, 67-70

135 Prognosis in Acute Myeloid Leukemia: Cytogenetics and Beyond **2014**, 49-57

134 Management of Therapy-Related Myeloid Neoplasms **2014**, 120-125

133 Management of Myelodysplastic Syndromes **2014**, 113-119

- 132 Cytogenetics and Prognostic Models in Myelodysplastic Syndromes **2014**, 106-112
- 131 Relapsed and Refractory Acute Myeloid Leukemia **2014**, 82-88
- 130 Minimal Residual Disease in Acute Myeloid Leukemia **2014**, 76-81
- 129 Mycosis Fungoides and Sézary Syndrome **2014**, 323-326
- 128 Diagnosis of Acute Lymphoblastic Leukemia **2014**, 1-17
- 127 Hematopoietic Cell Transplantation in Myelodysplastic Syndromes **2014**, 126-130
- 126 Hematopoietic Cell Transplantation in Acute Myeloid Leukemia **2014**, 89-95
- 125 Germ Cell Tumors **2014**, 645-650
- 124 Soft Tissue Sarcomas **2014**, 696-703
- 123 Hairy Cell Leukemia **2014**, 220-225
- 122 Primary Mediastinal Large B-Cell Lymphoma **2014**, 282-285
- 121 Methodological and Practical Challenges for Personalized Therapies in Non-Small-Cell Lung Cancer **2014**, 480-485
- 120 Hematopoietic Cell Transplantation in Hodgkin Lymphoma **2014**, 240-244
- 119 Medical Management of Melanoma **2014**, 651-660
- 118 Nonmelanoma Skin Cancers **2014**, 661-666
- 117 Ovarian Cancer: Neoadjuvant, Adjuvant, and Surgical Issues **2014**, 667-674
- 116 Bone Sarcomas **2014**, 687-695
- 115 Surgical Aspects of Head and Neck Cancers **2014**, 705-710

114 Surgical Aspects of Thoracic Malignancies **2014**, 711-718

113 Surgical Aspects of Upper Gastrointestinal Cancers **2014**, 719-722

112 Surgical Aspects of Pancreatic Cancer **2014**, 723-728

111 Surgical Aspects of Hepatobiliary Tumors **2014**, 729-734

110 Surgical Aspects of Lower Gastrointestinal Cancers **2014**, 735-738

109 Surgical Aspects of Renal Cancer **2014**, 739-743

108 Surgical Aspects of Bladder Cancer **2014**, 744-746

107 Surgical Aspects of Prostate Cancer **2014**, 747-753

106 Surgical Aspects of Melanoma **2014**, 754-758

105 Radiotherapy for Ductal Carcinoma in Situ (DCIS) **2014**, 767-770

104 Radiotherapy for Early-Stage Invasive Breast Cancer **2014**, 771-777

103 Radiotherapy for Thoracic Malignancies **2014**, 778-784

102 Radiotherapy for Gastrointestinal Malignancies **2014**, 785-788

101 Radiotherapy for Genitourinary Malignancies **2014**, 789-792

100 When to Suspect Hereditary Cancer Syndromes **2014**, 793-799

99 Hereditary Breast Cancer Syndromes **2014**, 800-803

98 Genetic Testing in Gastrointestinal Tumors **2014**, 804-809

97 Hereditary Urogenital Cancer Syndromes **2014**, 810-814

- 96 Geriatric Oncology **2014**, 822-825
- 95 Nuts and Bolts of Cancer Immunotherapy **2014**, 826-830
- 94 Controversies Related to Oncology Clinical Trial Development **2014**, 831-834
- 93 PET Scan in Oncology **2014**, 835-840
- 92 Hematopoietic Growth Factors **2014**, 841-843
- 91 Anticoagulation Issues in Oncology **2014**, 844-850
- 90 Symptom Management and Palliative Care **2014**, 851-859
- 89 Metabolic and Nutritional Issues in Oncology **2014**, 860-866
- 88 Bone-Related Issues in Oncology **2014**, 867-871
- 87 Integrative Medicine in Oncology **2014**, 872-878
- 86 Diagnostic Approach in Myeloproliferative Neoplasms **2014**, 135-141
- 85 Chronic Myeloid Leukemia: Chronic Phase **2014**, 142-146
- 84 Blast Crisis of Chronic Myeloid Leukemia **2014**, 147-149
- 83 Chronic Myeloid Leukemia and Pregnancy **2014**, 150-151
- 82 Polycythemia Vera **2014**, 152-155
- 81 Essential Thrombocytosis **2014**, 156-161
- 80 Primary Myelofibrosis **2014**, 162-166
- 79 Eosinophilic Myeloproliferative Disorders **2014**, 167-175

78 Chronic Myelomonocytic Leukemia **2014**, 176-179

77 Hematopoietic Cell Transplantation in Primary Myelofibrosis **2014**, 187-191

76 Prognostic Markers and Management of Chronic Lymphocytic Leukemia **2014**, 193-200

75 Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia **2014**, 201-206

74 Prolymphocytic Leukemia **2014**, 207-219

73 Management of Classical Hodgkin Lymphoma **2014**, 227-234

72 Nodular Lymphocyte-Predominant Hodgkin Lymphoma **2014**, 235-239

71 Pitfalls in the Diagnosis of Non-Hodgkin's Lymphomas **2014**, 245-256

70 Follicular Lymphoma **2014**, 257-262

69 Mantle Cell Lymphoma **2014**, 270-274

68 Marginal Zone Lymphoma **2014**, 275-281

67 Burkitt Lymphoma **2014**, 286-289

66 Gray Zone Lymphoma **2014**, 290-294

65 Transformed Lymphoma **2014**, 295-303

64 HIV-Associated Lymphoma **2014**, 304-307

63 Primary Cutaneous Lymphoma **2014**, 316-322

62 Hematopoietic Cell Transplantation in Indolent Non-Hodgkin's Lymphoma **2014**, 327-331

61 Hematopoietic Cell Transplantation in Diffuse Large B-cell Lymphoma **2014**, 332-338

- 60 Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin's Lymphomas **2014**, 339-344
- 59 Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance **2014**, 345-351
- 58 Risk Stratification and Response Assessment in Multiple Myeloma and Waldenström's Macroglobulinemia **2014**, 352-357
- 57 Treatment of Multiple Myeloma **2014**, 358-365
- 56 Light-Chain Amyloidosis **2014**, 366-370
- 55 Waldenström's Macroglobulinemia **2014**, 371-375
- 54 Autologous Hematopoietic Cell Transplantation in Multiple Myeloma **2014**, 376-380
- 53 Allogeneic hematopoietic cell transplantation in multiple myeloma **2014**, 381-387
- 52 Role of PET Scan in Lymphomas **2014**, 389-397
- 51 Radioimmunotherapy in Lymphomas **2014**, 398-402
- 50 Radiation Oncology Consultation for Hematologic Malignancies **2014**, 403-408
- 49 Donor and Graft Selection in Allogeneic Hematopoietic Cell Transplantation **2014**, 409-416
- 48 Preparative Regimens in Allogeneic Hematopoietic Cell Transplantation for Malignant Hematological Diseases **2014**, 417-420
- 47 T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation **2014**, 421-425
- 46 Prevention and Treatment of Relapse Following Hematopoietic Cell Transplantation **2014**, 426-431
- 45 Acute Graft-Versus-Host Disease **2014**, 432-437
- 44 Chronic Graft-Versus-Host Disease **2014**, 438-443
- 43 Primary Brain Tumors **2014**, 445-456



- 42 Secondary brain and spinal cord tumors **2014**, 457-464
- 41 Medical management of head and neck cancers **2014**, 465-475
- 40 Endocrine Malignancies **2014**, 476-479
- 39 Screening, Staging, and Stage I Non-Small-Cell Lung Cancer **2014**, 486-492
- 38 Stage II and III Non-Small-Cell Lung Cancer **2014**, 493-499
- 37 Recurrent and Metastatic Non-Small-Cell Lung Cancer and Novel Targets **2014**, 500-502
- 36 Small-Cell Lung Cancer **2014**, 503-505
- 35 Mesothelioma **2014**, 506-511
- 34 Immunohistochemistry Testing and Beyond in Breast Cancer **2014**, 513-522
- 33 Prevention and Adjuvant Therapy in Breast Cancer **2014**, 523-531
- 32 Preoperative Systemic Therapy for Breast Cancer **2014**, 532-539
- 31 Recurrent and Metastatic Breast Cancer **2014**, 540-545
- 30 Special Issues in the Young and Pregnant Patient with Breast Cancer **2014**, 546-552
- 29 Early-Stage Esophageal and Stomach Cancers **2014**, 553-561
- 28 Metastatic Esophagogastric Cancer: Controversies, Consensus, and New Targets **2014**, 562-566
- 27 Early-Stage Colorectal Cancer **2014**, 567-572
- 26 Recurrent and Metastatic Colorectal Cancer: Controversies, Consensus, and New Targets **2014**, 573-580
- 25 Hepatobiliary Cancer **2014**, 590-594

24 Neuroendocrine Tumors **2014**, 595-600

23 Transarterial Liver-Directed Therapies in Oncology **2014**, 601-605

22 Anal Cancer **2014**, 606-612

21 Renal Cancer: Tumor Diversity, Molecular Taxonomy, and Prognostic Algorithms **2014**, 613-620

20 Medical Management of Renal Cancer **2014**, 621-627

19 Medical Management of Bladder Cancer **2014**, 628-633

18 Prostate Cancer: Screening, Surveillance, Prognostic Algorithms and Independent Pathologic Predictive Parameters **2014**, 634-637

17 Medical Management of Prostate Cancer **2014**, 638-644

16 Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial. *Current Oncology Reports*, **2012**, 14, 480-2 6.3

15 Combination Cytotoxic and Antiangiogenic Therapy in the Management of Epithelial Ovarian Cancer. *Combination Products in Therapy*, **2011**, 1, 1

14 Response to: "Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis (Chua TC, et al.)". *Gynecologic Oncology*, **2009**, 115, 168 4.9

13 The myth of measurable disease in ovarian cancer: revisited. *Cancer Investigation*, **2009**, 27, 11-2 2.1

12 Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous. *Cancer*, **2010**, 116, 5116-8 6.4

11 Cisplatin/Epinephrine Injectable Gel. *Drugs and Aging*, **2001**, 18, 794-795 4.7

10 Should Cost Be Considered in the Overall Evaluation of Phase II Clinical Trials of New Antineoplastic Therapies? A Response to the Essay from Dr. Eddie Reed. *Cancer Investigation*, **1998**, 16, 142-143 2.1

9 Supportive care. *Cancer Chemotherapy and Biological Response Modifiers*, **2003**, 21, 709-16

8 Genetic discrimination arising from cancer risk assessments: a societal dilemma. *Cleveland Clinic Journal of Medicine*, **2004**, 71, 12, 15-8 2.8

7 Justification for separate consideration of two broad categories of cancer patient use of complementary medicine. *Society for Integrative Oncology*, **2007**, 5, 50-2

- 6 Supportive care. *Cancer Chemotherapy and Biological Response Modifiers*, **2002**, 20, 627-32
- 5 Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications. *Cancer Investigation*, **2005**, 23, 33-5 2.1
- 4 The role of intraperitoneal chemotherapy in ovarian cancer. *Clinical Advances in Hematology and Oncology*, **2006**, 4, 809-10 0.6
- 3 Risk of cervical cancer after HPV vaccination. *Current Pharmaceutical Design*, **2013**, 19, 1488-9 3.3
- 2 Precision medicine and the rapidly approaching future of cancer management. *American Journal of Managed Care*, **2012**, 18, SP207-8, cover 2.1
- 1 Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. *Journal of Cancer Research and Clinical Oncology*, **1997**, 123, 224-228 4.0